



PATENT  
Attorney Docket No. UCI-12094

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Robinson, *et al.*  
Serial No.: 10/672,724  
Filed: 09/25/03  
Entitled: **Novel HIV integrase inhibitors and HIV therapy based on drug combinations including integrase inhibitors**

Group No.: 1617  
Examiner: Wang

INFORMATION DISCLOSURE STATEMENT TRANSMITTAL

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

CERTIFICATE OF MAILING UNDER 37 CFR § 1.8(a)(1)(i)(A)

I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is, on the date shown below, being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date: August 24, 2006

By: Mary Ellen Waite

Mary Ellen Waite

Sir or Madam:

Enclosed please find an Information Disclosure Statement and Form PTO-1449, including copies of the references contained thereon, for filing in the U.S. Patent and Trademark Office. This Information Disclosure Statement is being filed before the issuance of a first Office Action, therefore, applicants' believe no fee is required.

The Commissioner is hereby authorized to charge any additional fee or credit overpayment to our Deposit Account No. 08-1290. An originally executed duplicate of this transmittal is enclosed for this purpose.

Dated: August 24, 2006

Jason R. Bond  
Registration No. 45,439

MEDLEN & CARROLL, LLP  
101 Howard Street, Suite 305  
San Francisco, California 94105  
608/218-6900




**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Robinson, <i>et al.</i>	Group No.: 1617
Serial No.: 10/672,724	Examiner: Wang
Filed: 09/25/03	
Entitled: <b>Novel HIV integrase inhibitors and HIV therapy based on drug combinations including integrase inhibitors</b>	

**INFORMATION DISCLOSURE STATEMENT**

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

<b>CERTIFICATE OF MAILING UNDER 37 CFR § 1.8(a)(1)(i)(A)</b>	
<p>I hereby certify that this correspondence (along with any referred to as being attached or enclosed) is, on the date shown below, being deposited with the U.S. Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.</p>	
Date: <u>August 24, 2006</u>	By:  Mary Ellen Waite

Sir or Madam:

The citations listed below may be material to the examination of the above-identified application, and are therefore submitted in compliance with the duty of disclosure defined in 37 C.F.R. §§ 1.56 and 1.97. The Examiner is requested to make these citations of official record in this application.

- U.S. Patent No. 5,705,647
- U.S. Patent No. 4,724,232
- WO 00/63152

- Robinson et al., "Inhibitors of HIV-1 replication that inhibit HIV integrase," PNAS 93:6326-6331 (1996)
- Deeks et al., "HIV-1 Protease Inhibitors," JAMA 277:145-153 (1997)
- Konig et al., "The Caffeoyletics as a New Family of Natural Antiviral Compounds," Naturwissenschaften 72:659-661 (1985)
- King et al., "Resistance to the Anti-Human Immunodeficiency Virus Type 1 Compounds L-Chicoric Acid Results from a Single Mutation at Amino Acid 140 of Integrase," J. of Virology 72:8420-8424 (1998)
- King et al., "Structure-Activity Relationships: Analogues of the Dicafeoylquinic and Dicafeoyltartaric Acids as Potent Inhibitors of Human Immunodeficiency Virus Type 1 Integrase and Replication, J. Med. Chem. 42:497-509 (1999)
- Starnes et al., "Cellular Metabolism of 2',3'-Dideoxycytidine, a Compounds Active against Human Immunodeficiency Virus in Vitro," J. Biol Chem. 262:988-991 (1987)
- Robinson, Jr., "L-Chicoric acid, an inhibitor of human immunodeficiency virus type 1 (HIV-1) integrase, improves on the in vitor anti-HIV-1 effect of Zidovudine plus a protease inhibitor (AG1350)," Antiviral Res. 39:101-111 (1998)
- McDougall et al., "Dicafeoylquinic and Dicafeoyltartaric Acids Are Selective Inhibitors of Human Immunodeficiency Virus Type 1 Integrase," Antimicrobial Agents and Chemotherapy 42:140-146 (1998)
- Beale et al., "Combinations of reverse transcriptase, protease, and integrase inhibitors can be synergistic in vitro against drug-sensitive and RT inhibitor-resistant molecular clones of HIV-1," Antiviral Res. 45:223-232 (2000)
- Farnet et al., "Human Immunodeficiency Virus Type 1 cDNA Integration: New Aromatic Hydroxylated Inhibitors and Studies of the Inhibition Mechanism," Antimicrobial Agents and Chemotherapy 42:224502253 (1998)


Applicants herewith submit copies of the International Search Report and the International Preliminary Examination Report from the corresponding International Application Serial No. PCT/US99/06700.

Applicants wish to bring to the examiners attention that we are not providing copies of U.S. Patents as instructed under 37 CFR 1.98(a)(2).

This Information Disclosure Statement under 37 C.F.R. §§ 1.56 and 1.97 is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one or more of these citations constitutes prior art.

Dated: \_\_\_\_\_

08/24/06

  
\_\_\_\_\_  
Jason R. Bond  
Registration No. 45,439  
MEDLEN & CARROLL, LLP  
101 Howard Street, Suite 350  
San Francisco, California 94105  
608/218-6900

PTO/SB/08A (08-03)  
Approved for use through 07/31/2006. OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE  
is a collection of information unless it contains a valid OMB control number.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	10/672,724
		Filing Date	9/25/2003
		First Named Inventor	Robinson et al.
		Art Unit	1617
		Examiner Name	Wang
Sheet 2	of 2	Attorney Docket Number	UCI-12094

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	4	Robinson et al., "Inhibitors of HIV-1 replication that inhibit HIV integrase," PNAS 93:6326-6331 (1996)	
	5	Deeks et al., "HIV-1 Protease Inhibitors," JAMA 277:145-153 (1997)	
	6	Konig et al., "The Caffeyolys as a New Family of Natural Antiviral Compounds," Naturwissenschaften 72:659-661 (1985)	
	7	King et al., "Resistance to the Anti-Human Immunodeficiency Virus Type 1 Compounds L-Chicoric Acid Results from a Single Mutation at Amino Acid 140 of Integrase," J. of Virology 72:8420-8424 (1998)	
	8	King et al., "Structure-Activity Relationships: Analogues of the Dicafeoylquinic and Dicafeoyltartaric Acids as Potent Inhibitors of Human Immunodeficiency Virus Type 1 Integrase and Replication, J. Med. Chem. 42:497-509 (1999)	
	9	Starnes et al., "Cellular Metabolism of 2',3'-Dideoxycytidine, a Compounds Active against Human Immunodeficiency Virus in Vitro," J. Biol Chem. 262:988-991 (1987)	
	10	Robinson, Jr., "L-Chicoric acid, an inhibitor of human immunodeficiency virus type 1 (HIV-1) integrase, improves on the in vitor anti-HIV-1 effect of Zidovudine plus a protease inhibitor (AG1350)," Antiviral Res. 39:101-111 (1998)	
	11	McDougall et al., "Dicafeoylquinic and Dicafeoyltartaric Acids Are Selective Inhibitors of Human Immunodeficiency Virus Type 1 Integrase," Antimicrobial Agents and Chemotherapy 42:140-146 (1998)	
	12	Beale et al., "Combinations of reverse transcriptase, protease, and integrase inhibitors can be synergistic in vitro against drug-sensitive and RT inhibitor-resistant molecular clones of HIV-1," Antiviral Res. 45:223-232 (2000)	
	13	Farnet et al., "Human Immunodeficiency Virus Type 1 cDNA Integration: New Aromatic Hydroxylated Inhibitors and Studies of the Inhibition Mechanism," Antimicrobial Agents and Chemotherapy 42:224502253 (1998)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.